- Home
- GLQ vs CHRS Comparison
GLQ vs CHRS Comparison
Compare GLQ & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLQ | CHRS |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.4M | 159.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GLQ | CHRS |
|---|---|---|
| Price | $7.49 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 39.3K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 11.11% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.55 |
| Revenue Next Year | N/A | $63.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.27 | $0.57 |
| 52 Week High | $8.75 | $2.62 |
Technical Indicators
Market Signals| Indicator | GLQ | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 29.44 |
| Support Level | $7.31 | N/A |
| Resistance Level | $7.76 | $1.53 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 44.59 | 6.16 |
Price Performance
Historical ComparisonAbout GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.